Browse drugs

… treatments were of very low certainty. For endoscopic relapse, vedolizumab probably reduced the risk of relapse (moderate certainty), RR 0…

…yes of 148 patients diagnosed with NIU were treated with either originator adalimumab (n=193, 74.23%) or a biosimilar (n=67, 25.77%). Median follow-u…

…dy included 314 anti-TNF treatment courses (212 infliximab, 102 adalimumab) in 248 patients at a tertiary centre in the United Arab Emirat…

…l surgery.Advanced therapies used for treatment of OFG included adalimumab (n=56), infliximab (n=52), ustekinumab (n=23), risankizumab (n=…

…pport co-prescribing. We describe our experience of prescribing benralizumab alongside non-SA MAbs at a tertiary centre.Methods We conducted…

…ngle-arm trials. Fourteen studies evaluated biologic therapies: infliximab (n=5), adalimumab (n=2), etanercept (n=2), golimumab (n=1), rit…

…iagnosed with Crohn’s disease at age 10. Initially treated with infliximab, he was switched to adalimumab due to allergic reaction. He did…

…ad documented clinical response or remission after switching to ustekinumab. 2 patients not responding subsequently switched from ustekinum…

…ar– Difficulties using the pen deviceProjected annual savings:– Amgevita®: £86,000– Benepali®: £34,000Conclusion Several challenges emer…

…from real-world clinical practice (RWE) remains limited.Methods Adalimumab vs Ixekizumab Real-world Effectiveness is a multicentre cohort …

…ey role in HS pathophysiology, making IL-17 inhibitors, such as secukinumab, a therapeutic option.Aim and Objectives To assess the effectiv…

…ntre study in SH adult patients receiving biological treatment (adalimumab, secukinumab or bimekizumab) at a general hospital (March-June …